Results 21 to 30 of about 12,412 (210)

Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs

Mediators of Inflammation, 2020
Secukinumab is a novel IL-17A inhibitor that has been confirmed to be effective for treating PsA and RA. Several studies have demonstrated that secukinumab also provides benefits for AS patients. Thus, we performed a meta-analysis of RCTs to evaluate the
Yu Zhou, Jinhui Ma, Juncheng Ge, Bailiang Wang, Debo Yue, Weiguo Wang   +5 more
doaj   +1 more source

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5

Chinese Medical Journal, 2020
. Background. Secukinumab demonstrated sustained efficacy in patients with ankylosing spondylitis (AS) through 5 years in pivotal Phase III studies.
Feng Huang, Fei Sun, Wei-Guo Wan, Li-Jun Wu, Ling-Li Dong, Xiao Zhang, Tae-Hwan Kim, Raj Sengupta, Ladislav Šenolt, Yi Wang, Hao-Min Qiu, Brian Porter, Sibylle Haemmerle, Li-Shao Guo   +13 more
doaj   +1 more source

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

RMD Open, 2018
Objective To assess the long-term (3 year) efficacy and safety of secukinumab in patients with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study (NCT01892436).Methods Following the 2-year core trial, eligible patients ...
Philip J Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Jürgen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Evie Maria Delicha, Shephard Mpofu, Luminita Pricop   +10 more
doaj   +1 more source

Secukinumab for rheumatology: development and its potential place in therapy [PDF]

, 2016
Contains fulltext : 165772.pdf (Publisher’s version ) (Open Access)Rheumatic disease is not a single disorder, but a group of more than 100 diseases that affect joints, connective tissues, and/or internal organs.
Koenders MI, van den Berg WB, Berg, W.B. van den, Koenders, M.I.   +3 more
core   +2 more sources

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis

Rheumatology and Therapy, 2023
Introduction This study evaluated the efficacy of the interleukin-17A inhibitor secukinumab in patients with oligoarticular psoriatic arthritis (PsA). Methods A total of 84 patients with oligoarticular PsA, defined as 1–4 tender joints and 1–4 swollen ...
Alexis Ogdie, Dafna D. Gladman, Laura C. Coates, Effie Pournara, Bhumik Parikh, Philip J. Mease   +5 more
doaj   +1 more source

Efficacy of secukinumab on dactylitis in patients with active psoriatic arthritis from the FUTURE 5 study

, 2022
OBJECTIVES: Dactylitis is an important clinical domain of psoriatic arthritis (PsA) associated with significant burden of disease and impaired function.
Erhard Quebe-Fehling, Kirkham, Bruce, Philip J. Mease, Bruce Kirkham, Mease, Philip J, Corine Gaillez, Nash, Peter, Sandra Navarra, Navarra, Sandra, Delia Reina, Carlos Sastre, Reina, Delia, Gaillez, Corine, Quebe-Fehling, Erhard, Peter Nash, Sastre, Carlos   +15 more
core   +1 more source

Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review

Drugs - Real World Outcomes, 2019
Objectives To characterize US patients with ankylosing spondylitis (AS) who were treated with secukinumab and to assess rheumatologist-reported reasons for prescribing treatment in clinical practice.
Reeti Joshi, Dominick Latremouille-Viau, Mark K. Meiselbach, Jipan Xie, Yujin Park, Prashanth Sunkureddi   +5 more
doaj   +1 more source

Comparison of secukinumab versus adalimumab efficacy on skin outcomes in psoriatic arthritis: 52-week results from the EXCEED study

, 2021
Background/Aims  Psoriatic arthritis (PsA) is a heterogeneous disease comprising musculoskeletal and dermatological manifestations, especially plaque psoriasis.
Pellet, Pascale, Pricop, Luminita, Merola, Joseph F, McInnes, Iain, Behrens, Frank, Gottlieb, Alice, Nash, Peter   +6 more
core   +1 more source

Bimekizumab versus Secukinumab in Plaque Psoriasis

, 2021
BACKGROUND: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively inhibits interleukin-17A alone, in patients ...
Vanvoorden, Veerle, Warren, Richard B, Blauvelt, Andrew, Peterson, Luke, Cioffi, Christopher, Reich, Kristian, Paul, Carle, De Cuyper, Dirk, Gooderham, Melinda, Langley, Richard G, Lebwohl, Mark, Strober, Bruce, Madden, Cynthia   +12 more
core   +1 more source

Secukinumab demonstrated high efficacy in clearing nail psoriasis: Results from posthoc analyses from the phase III programs

, 2020
Introduction: Nail psoriasis occurs in 50%-70% of patients with psoriasis (PsO) and 60%- 80% of patients with psoriatic arthritis (PsA). Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has proven highly efficacious in the ...
Gaillez, Corine, Kirkham, Bruce, Aassi, Maher, Elewski, Boni, Reich, Kristian, Bao, Weibin, Frueh, Jennifer A, Nash, Peter   +7 more
core   +1 more source